21世纪经济报道记者 韩利明 上海报道 日前，华熙生物在官微发布《概念总在重演，科技永远向前》一文，直指资本市场不断追求新的公司题 材，为了营造比透明质酸产业更大的预期，围绕某重组胶原企业的研报中，出现了大量直接针对中国透 明质酸产业的"对比研究"。 一时间，有关"透明质酸（玻尿酸）与重组胶原蛋白""华熙生物'炮轰'券商"的讨论持续发酵。 5月21日晚间，华熙生物再次发文回应，坦言作为在资本市场经历过第一轮完整周期的企业，深切体会 概念切换对企业经营带来的影响，"正是因为现在经营环境面临挑战，华熙生物才会更多体会到行业中 众多企业的难处，才会有新的角度审视产业的生态环境，才会与所有的同行一起审视这个环境有哪些因 素在鼓励价值创造，有哪些是在导致价值损耗。" 不可否认，自2022年登顶业绩巅峰后，华熙生物近两年来直面营收和净利润双降的压力，2024年更是启 动一次包括业务流程重塑、组织与人才变革、指标与绩效体系变革、推动企业数智化等多个项目在内的 全面的管理变革。 在此背景下，这场关于产业生态中"资本逐利"与"科技长期主义"的公开博弈，也是对行业发展逻辑的深 层叩问。摆脱概念炒作窠臼，以技术壁垒构建可持续的产业 ...

饲料养殖产业日报 日度观点 ◆生猪： 5 月 22 日辽宁现货 14.2-14.5 元/公斤，较上一日稳定；河南 14.4-15 元/公 斤，较上一日跌 0.1 元/公斤；四川 14.2-14.5 元/公斤，较上一日稳定；广 东 15-15.5 元/公斤，较上一日稳定。5 月规模企业出栏计划增加，且生猪体 重高位，供应压力累积中，前期二育强势进场，随着部分养殖户加快出栏节 奏，短期供应压力释放。需求端，虽然端午节备货临近，但天气转热，猪肉 消费转淡，且猪价偏高，屠企利润仍亏损，需求难有明显增量，不过低位二 次育肥滚动进场仍存，整体供需博弈加剧，猪价频繁震荡整理，关注企业出 栏节奏、二育进出情况、体重变化。中长期来看，能繁母猪存栏 2024 年 5- 11 月缓增，生产性能提升，在疫情平稳情况下，5-9 月供应呈增加态势， 根据仔猪数据，2024 年 11-2025 年 2 月仔猪同比增加，二季度出栏压力仍 大，叠加生猪体重偏高，而上半年消费淡季，在供强需弱格局下， 猪价仍 有下跌风险，关注二育介入造成供应后移、冻品出入库以及饲料价格波动对 价格的扰动；2024 年 12 月开始，生猪产能有所去化，但行业有利润 ...

昨日北交所分化显著，北证50指数一路走高，创下1479.81的历史最高收盘价和1500.31的历史最高价， 有望正式开启1500点新时代 。 与之形成鲜明对比的，北证全A指数跌了近1个点，266只个股有205只下跌。这是否是北研君先前说 的"强拉指数"的延续？非也，因为就连北证50成分股中也只有12家上涨，之中涨幅最大的是锦波生物， 在重组蛋白行情的炒作下单日上涨9.17%，其目前500亿的总市值放在3000亿的北证50盘子中，权重已 达到顶格的10%， 因此其一只股票给指数贡献的涨幅就超过0.9%，可谓一人之力带动北证50再创新高 随后，中美达成贸易协议， 航运主题接棒 ，北交所国航远洋当选排头是比较容易判断的，从5月12日到 5月14日， 股价涨了81.09% （包含1个板），15日开始放量兑现。 如此算来，北证50指数近三日涨了4%，锦波涨了20个点， 为北证50贡献了一半，是本轮指数创新高 的"掌舵人" 。当然除了"掌舵人"，题材之间的持续炒作、不断轮动，以保证健康的交易量和积极情绪， 也是创新高的必要条件。那么本轮行情中题材是怎样轮动的呢？ "五一"后，受假期期间地缘事件影响， 军工股开始异动 ，5 ...

面对连续四年累计亏损超4亿元、被ST的风险，该公司的股价依旧连续大幅上扬，从5月6日至今，已累 计斩获10个涨停，涨幅高达60%以上。 资本狂欢的引爆点，既有"白衣骑士"接盘带来的重组预期，亦有机构、游资的接力炒作。近期，多个活 跃券商等席位频繁现身在龙虎榜现身，推动该股20个交易日内实现翻倍。 随着股价大幅上涨，接盘方尚未正式入主，便已浮盈3.7亿元，而潜伏其中的"牛散"谢恺，更是借势斩 获6000万收益， 被*ST后股价连涨 其股价自5月6日以来，已斩获10个涨停，累计涨幅逾60%。 深陷退市危机的*ST亚振（603389.SH），正在上演"逆袭"戏码。 截至5月21日收盘，*ST亚振再次上涨2.68%，报收于10.34元/股。 Wind数据显示，5月6日至21日，该股已有10个交易日涨停，累计涨幅超60%。*ST亚振接连提示风险 称，目前生产经营活动正常，市场环境或行业政策没有发生重大调整、内部生产经营秩序正常，不存在 应披露而未披露的重大信息。 此番大涨前，*ST亚振刚因业绩疲软被实施退市风险提示。年报显示，2024年，该公司营业总收入2.02 亿元，净利润为-1.17亿元，扣非净利润亏损1.16亿元 ...

Core Viewpoint - The company has experienced a significant stock price increase of over 300% since March 2025, which is not supported by its fundamental performance, leading to concerns about market speculation and potential risks [3]. Group 1: Stock Performance and Risks - The company's A-share stock has risen by 312.90% from March 10 to May 20, 2025, despite no major changes in its fundamentals, and it is currently in a loss position for 2024 [3]. - The company reported a net profit of -14.08 million yuan for 2024, but a profit of 13.76 million yuan in the first quarter of 2025, indicating a turnaround from a loss of -10.39 million yuan in the same period last year [3]. - The company has warned of high speculation risks and a significant deviation from its fundamental value, as its price-to-book ratio is much higher than the industry average [3]. Group 2: Financial Health and Profitability - The company has a substantial goodwill on its balance sheet, with a goodwill impairment loss of approximately 50 million yuan in 2023 and a goodwill value of about 160 million yuan as of the end of the first quarter of 2025 [3][4]. - The company has accumulated undistributed profits of approximately -2.1 billion yuan, which will be prioritized to cover previous losses before any cash dividends can be distributed [4]. - The company faces a long-term risk of not being able to distribute dividends until it has compensated for its past losses [4]. Group 3: Product Information and Market Conditions - The company has not disclosed any plans to reveal the revenue or profit contribution from its dibutyl phthalate (DBP) production, citing it as a commercial secret [2][5]. - The price of dibutyl phthalate has seen significant increases, with prices reported at 69,700 yuan per ton as of April 4, 2025, reflecting a 45.2% increase since the beginning of the year [6]. - The company has indicated that its production facilities can produce various types of phthalates, but it has not provided specific capacity details for its dibutyl phthalate production [6].

Core Viewpoint - The article highlights a conflict in the biopharmaceutical industry regarding the competition between hyaluronic acid and recombinant collagen, with Huaxi Biological criticizing the notion that hyaluronic acid is outdated, which they attribute to capital-driven speculation [1][4]. Company Performance - Huaxi Biological's performance has declined significantly, with projected revenue for 2024 expected to decrease by 11.61% and net profit to drop by 70.59%, resulting in a market capitalization loss of over 100 billion [1][6]. - In contrast, Juzhi Biological has experienced substantial growth, with a projected revenue increase of 57.2% and net profit growth of 42.4% for 2024, leading to a doubling of its market capitalization [1][6]. Market Dynamics - The article discusses the contrasting market performances of Huaxi Biological and Juzhi Biological, indicating a clear divide in the industry, with Huaxi's stock price falling over 80% from its peak of 309.43 yuan per share in July 2021 to 53.08 yuan per share as of May 20, 2025, resulting in a market cap of less than 25.6 billion [9][6]. - Juzhi Biological's stock has seen a significant increase, reaching a peak of 86.45 HKD, representing a cumulative rise of over 44% from approximately 60 HKD at the end of 2024 [8][6].

Group 1 - The stock of Zhongyida (600610) experienced significant volatility, reaching a peak increase of over 300% year-to-date, but later faced a sharp decline, dropping approximately 3% as of the latest report [2] - The company announced that from March 10 to May 20, 2025, its A-share stock had a cumulative increase of 312.90%, despite no major changes in its fundamentals, indicating a potential overheating of market sentiment and high speculation risk [2] - For the fiscal year 2024, the company reported a net loss of 14.08 million yuan, while the first quarter of 2025 showed a net profit of 13.76 million yuan, marking a turnaround from a loss of 10.39 million yuan in the same period last year [2] Group 2 - The acquisition of Chifeng Ruiyang resulted in significant goodwill, which requires annual impairment testing according to accounting standards; in 2023, the company recognized a goodwill impairment loss of 49.99 million yuan, while no impairment loss was recorded for 2024 [3] - As of the end of the first quarter of 2025, the company's goodwill was valued at 160.03 million yuan, exceeding its net asset value of 81.01 million yuan, indicating a risk of further goodwill impairment if the operational conditions of Chifeng Ruiyang do not improve [3] - The company reported a cumulative retained earnings deficit of 2.098 billion yuan as of December 31, 2024, and any profits will be used to offset previous losses, posing a long-term risk of being unable to distribute cash dividends until the losses are fully addressed [3]

| I C E H Ho | | 投资咨询业务资格:证监许可【 | | --- | --- | --- | | | | 日博策略参 | | | | 发布日期:2025/05 | | 行业板块 趋势研判 品种 | | 逻辑观点精粹及策略参考 | | | | 随着市场对关税冲击的波动与政策护盘动能趋于衰减,加上当前 | | 股指 震荡 | | 反弹已至区间上沿,在缺乏增量催化因素的背景下,短期或转入 | | | | 震荡整固阶段,策略上、短线多单考虑冲高止盈, 警惕调整风险 | | 宏观金融 震荡 | | 资产荒和弱经济利好债期,但短期央行提示利率风险,压制上涨 | | 国债 | | 空间。 | | 賣金 農汤 | | 多空交织，短期金价或盘整震荡;但中长期上涨逻辑尚未改变。 | | 白银 震荡 | C B | 跟随黄金宽幅震荡, 但中期上方空间有限。 | | 看空 第四 | | 近期国内外宏观数据偏弱压制市场风险偏好,叠加铜下游需求有 | | | | 所转弱,铜价短期偏弱运行。 | | 農汤 | | 近期电解铝低库存对铝价仍有支撑,但随着铝价走高,上行空间 | | | | 受限,预计近期震荡运行。 | | 氢化 ...

Core Viewpoint - The company, Zhongyida (600610), has announced significant fluctuations in its A-share stock price and may apply for a trading suspension if abnormal trading continues, aiming to protect the rights of small investors [1] Summary by Relevant Sections Stock Performance - From March 10, 2025, to May 20, 2025, the company's A-share stock has experienced a cumulative increase of 312.90% [1] Financial Condition - The company is projected to incur losses in the fiscal year 2024, indicating a deteriorating financial situation despite the stock price surge [1] - The company's price-to-book ratio is significantly higher than the industry average, suggesting overvaluation [1] Market Sentiment - The stock price is seen as severely detached from the company's fundamental performance, indicating a potential overreaction in market sentiment and a high risk of speculation [1]

Core Viewpoint - The solid-state battery sector experienced a significant surge on May 21, driven by the unveiling of multiple new products at the 17th Shenzhen International Battery Technology Exchange Conference, with notable stocks like Lingpai Technology and others reaching their daily limit up [2][5]. Group 1: Company Developments - Lingpai Technology, a state-owned enterprise in Hunan, shifted its focus to solid-state battery research and development after transitioning to the new energy battery sector in 2022 [2]. - The company announced that its wholly-owned subsidiary, Suzhou Lingpai, has completed foundational tests for solid-state electrolytes and batteries, achieving an energy density of 240Wh/kg with the high-voltage VDA355 module and has applied for relevant patents [2]. - Lingpai Technology plans to establish the world's first GWh-level repair-type solid-state battery testing line at its Jiangsu Jintan base by April 2025, with mass production of compatible products expected in 2026 [2][4]. Group 2: Technological Advantages - The core technological advantages of Lingpai Technology in the solid-state battery field include a "lithium replenishment" repair technology that extends battery cycle life to 80,000 times, nearly ten times the industry average [4]. - The company has developed a solid-state battery that operates stably in a wide temperature range of -40℃ to 100℃, in collaboration with the Fudan team, utilizing lithium trifluoromethanesulfonate [4]. - Lingpai Technology's solid-state battery technology has been applied in emerging scenarios such as drones and low-altitude aircraft, with a 5000mAh high-capacity battery designed to meet the lightweight requirements of eVTOL (electric vertical takeoff and landing) aircraft [4]. Group 3: Financial Performance - Despite significant technological breakthroughs, Lingpai Technology faces considerable financial pressure, with a debt-to-asset ratio of 93% and a current ratio of 0.8 as of the end of Q1 2025, indicating liquidity risks [5]. - The company's operating cash flow was negative at -28.48 million yuan, with short-term borrowings increasing by 252.33% year-on-year, intensifying repayment pressures [5]. - Lingpai Technology has increased its R&D investment, with Q1 2025 R&D expenses reaching 7.78 million yuan, a 34.53% increase year-on-year, accounting for 17.4% of revenue, significantly above the industry average [5].